Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Ratio (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Equity Ratio for 13 consecutive years, with 0.48 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 33.89% to 0.48 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.48 through Dec 2025, down 33.89% year-over-year, with the annual reading at 0.48 for FY2025, 33.89% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.48 at Madrigal Pharmaceuticals, up from 0.46 in the prior quarter.
  • The five-year high for Equity Ratio was 0.84 in Q1 2021, with the low at 0.07 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.58, with a median of 0.67 recorded in 2022.
  • The sharpest move saw Equity Ratio tumbled 91.28% in 2022, then soared 674.46% in 2024.
  • Over 5 years, Equity Ratio stood at 0.72 in 2021, then fell by 24.12% to 0.54 in 2022, then increased by 16.23% to 0.63 in 2023, then grew by 14.38% to 0.72 in 2024, then tumbled by 33.89% to 0.48 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.48, 0.46, and 0.69 for Q4 2025, Q3 2025, and Q2 2025 respectively.